American Vietnamese Biotech Incorporation (HNX:AMV)
Vietnam
· Delayed Price · Currency is VND 1,700.00
-100.00 (-5.56%)
At close: Apr 28, 2026
HNX:AMV Income Statement
Financials in millions VND. Fiscal year is January - December.
Millions VND. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2017 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2017 |
| Revenue | 154,067 | 310,355 | 196,570 | 281,818 | 223,843 | Upgrade
|
| Revenue Growth (YoY) | -50.36% | 57.88% | -30.25% | 25.90% | 38.66% | Upgrade
|
| Cost of Revenue | 132,371 | 279,093 | 146,978 | 202,869 | 110,149 | Upgrade
|
| Gross Profit | 21,696 | 31,261 | 49,592 | 78,949 | 113,694 | Upgrade
|
| Selling, General & Admin | 49,279 | 35,574 | 17,122 | 15,478 | 14,028 | Upgrade
|
| Operating Expenses | 49,279 | 35,574 | 17,122 | 15,478 | 14,028 | Upgrade
|
| Operating Income | -27,583 | -4,313 | 32,471 | 63,472 | 99,666 | Upgrade
|
| Interest Expense | -18,539 | -19,650 | -23,353 | -20,309 | -18,124 | Upgrade
|
| Interest & Investment Income | 2,314 | 739.98 | 1,153 | 2,511 | 3,482 | Upgrade
|
| Earnings From Equity Investments | -6,073 | -1,886 | - | - | - | Upgrade
|
| Currency Exchange Gain (Loss) | - | 643.38 | 1,164 | - | - | Upgrade
|
| Other Non Operating Income (Expenses) | -4,343 | 1,767 | -1,625 | 10,812 | -3,417 | Upgrade
|
| EBT Excluding Unusual Items | -54,224 | -22,699 | 9,809 | 56,487 | 81,608 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | 11,209 | 1,641 | - | - | Upgrade
|
| Pretax Income | -54,224 | -11,491 | 11,450 | 56,487 | 81,608 | Upgrade
|
| Income Tax Expense | 280.08 | 1,575 | 718.26 | 1,316 | - | Upgrade
|
| Earnings From Continuing Operations | -54,504 | -13,065 | 10,732 | 55,171 | 81,608 | Upgrade
|
| Minority Interest in Earnings | 1,454 | 1,874 | -47.13 | -1,239 | 631.67 | Upgrade
|
| Net Income | -53,049 | -11,191 | 10,685 | 53,931 | 82,240 | Upgrade
|
| Net Income to Common | -53,049 | -11,191 | 10,685 | 53,931 | 82,240 | Upgrade
|
| Net Income Growth | - | - | -80.19% | -34.42% | 5.36% | Upgrade
|
| Shares Outstanding (Basic) | 131 | 131 | 131 | 107 | 84 | Upgrade
|
| Shares Outstanding (Diluted) | 131 | 131 | 131 | 107 | 84 | Upgrade
|
| Shares Change (YoY) | -0.09% | - | 22.04% | 27.63% | 58.37% | Upgrade
|
| EPS (Basic) | -405.00 | -85.36 | 81.50 | 502.00 | 977.00 | Upgrade
|
| EPS (Diluted) | -405.00 | -85.36 | 81.00 | 502.00 | 977.00 | Upgrade
|
| EPS Growth | - | - | -83.86% | -48.62% | -33.47% | Upgrade
|
| Free Cash Flow | 246,626 | 628,530 | -144,792 | -347,688 | -510,894 | Upgrade
|
| Free Cash Flow Per Share | 1882.84 | 4794.07 | -1104.39 | -3236.32 | -6069.36 | Upgrade
|
| Gross Margin | 14.08% | 10.07% | 25.23% | 28.01% | 50.79% | Upgrade
|
| Operating Margin | -17.90% | -1.39% | 16.52% | 22.52% | 44.52% | Upgrade
|
| Profit Margin | -34.43% | -3.61% | 5.44% | 19.14% | 36.74% | Upgrade
|
| Free Cash Flow Margin | 160.08% | 202.52% | -73.66% | -123.37% | -228.24% | Upgrade
|
| EBITDA | 5,327 | 12,012 | 54,302 | 83,871 | 115,543 | Upgrade
|
| EBITDA Margin | 3.46% | 3.87% | 27.63% | 29.76% | 51.62% | Upgrade
|
| D&A For EBITDA | 32,910 | 16,325 | 21,832 | 20,399 | 15,877 | Upgrade
|
| EBIT | -27,583 | -4,313 | 32,471 | 63,472 | 99,666 | Upgrade
|
| EBIT Margin | -17.90% | -1.39% | 16.52% | 22.52% | 44.52% | Upgrade
|
| Effective Tax Rate | - | - | 6.27% | 2.33% | - | Upgrade
|
| Revenue as Reported | 154,067 | 310,355 | 196,570 | 281,818 | 223,843 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.